Hypothesis

Rationale

Baseline microbiome stratification using resistance biomarkers (Bacteroides stercoris, Prevotella copri, Bacteroides vulgatus) predicts non‑response to generic probiotics, while responders enrich in Collinsella aerofaciens 2. Precision psychobiotics such as Akkermansia muciniphila and Parabacteroides goldsteinii have shown cognitive benefits via SCFA production, anti‑inflammatory effects, and restoration of hippocampal activity 14. However, no trial has prospectively combined biomarker screening with targeted strain administration for cognitive endpoints.

Mechanistic Insight

We propose that enrichment of Akkermansia muciniphila and Parabacteroides goldsteinii elevates luminal propionate and butyrate, which stimulate enteroendocrine L‑cells to release GLP‑1 and PYY. These gut hormones activate vagal afferents, increasing hippocampal BDNF expression through TrkB‑mediated signaling and enhancing GABAergic tone that stabilizes neuronal networks during memory consolidation. Simultaneously, reduced luminal LPS due to strengthened gut barrier lowers microglial priming, shifting microglia toward a homeostatic phenotype that supports synaptic plasticity.

Predictions

1. Participants screened low for resistance biomarkers and given a 12‑week cocktail of Akkermansia muciniphila + Parabacteroides goldsteinii will show a significant increase in fecal propionate/butyrate and plasma GLP‑1 compared with placebo.
2. This metabolic shift will correlate with heightened vagal tone (elevated HF‑HRV) and increased hippocampal BDNF levels measured via PET or CSF.
3. Cognitive composites (episodic memory, executive function) will improve significantly in the treatment group, with effect sizes exceeding those seen in untargeted probiotic trials.
4. The cognitive benefit will persist at 6‑month follow‑up only in participants who maintain enrichment of the administered strains.

Experimental Design

• Design: Double‑blind, placebo‑controlled RCT.
• Population: 200 adults aged 50‑70 with mild cognitive impairment (MoCA 22‑26).
• Stratification: Baseline stool metagenomics to quantify Bacteroides stercoris, Prevotella copri, Bacteroides vulgatus; participants classified as low‑risk (below threshold) vs high‑risk.
• Intervention: Daily sachet containing 10^9 CFU each of Akkermansia muciniphila and Parabacteroides goldsteinii, enteric‑coated to survive gastric transit.
• Control: Iso‑osmolar placebo sachet.
• Outcomes: Primary – change in ADAS‑Cog13 at 12 weeks. Secondary – fecal SCFA concentrations, plasma GLP‑1/PYY, HF‑HRV, hippocampal BDNF (PS‑PET), microbiome composition, adverse events.
• Analysis: Mixed‑effects models testing interaction between treatment, baseline risk status, and time; mediation analysis to test whether SCFA/vagal changes mediate cognitive gains.

Potential Outcomes and Falsifiability

If the treatment group fails to show increased SCFA, GLP‑1, or vagal tone despite strain enrichment, or if cognitive scores do not diverge from placebo, the hypothesis is falsified. Conversely, demonstration of the proposed mechanistic cascade would validate precision psychobiotic strategy and provide a biomarker‑driven pathway for microbiome‑based cognitive enhancement.